OBJECTIVES: There is a need for a brief symptom index for advanced kidney cancer that includes perspectives of both patients and clinicians and is consistent with the Food and Drug Administration's guidance for patient-reported outcome measures. This study developed and examined the preliminary reliability and validity of the new National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index 19. METHODS: Fifty patients with advanced kidney cancer provided open-ended and survey responses ranking their most important symptoms. Responses were reconciled with published clinician reports of the most important symptoms. Ten experienced oncologists rated symptoms as disease- or treatment-related. Patients completed quality-of-life and performance status measures. RESULTS: A 19-item index was produced from symptoms that were rated as most important by patients or clinicians. It includes three subscales: disease-related symptoms (DRS), treatment side effects (TSE), and general function and well-being (FWB). Internal consistency was good for the full instrument (α = 0.83), the DRS subscale (α = 0.76), and the FWB subscale (α = 0.78) but lower for the TSE subscale (α = 0.59). Convergent validity was demonstrated through correlations with the FACT-General. Patients with differing performance status were distinguished by the total score (F2,47 = 17.37; P < .0001), the DRS subscale (F2,47 = 14.22; P < .0001), and the FWB subscale (F2,47 = 13.40; P < .0001) but not the TSE subscale (F2,47 =1.48; P = 0.2380). CONCLUSIONS: The National Comprehensive Cancer Network/FACT-Kidney Symptom Index 19 combines symptoms deemed most important by patients and clinicians. Preliminary evidence suggests that the total score and DRS and FWB subscales are reliable and valid as summary indexes. The TSE subscale may be least relevant given the advent of newer therapies.
OBJECTIVES: There is a need for a brief symptom index for advanced kidney cancer that includes perspectives of both patients and clinicians and is consistent with the Food and Drug Administration's guidance for patient-reported outcome measures. This study developed and examined the preliminary reliability and validity of the new National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index 19. METHODS: Fifty patients with advanced kidney cancer provided open-ended and survey responses ranking their most important symptoms. Responses were reconciled with published clinician reports of the most important symptoms. Ten experienced oncologists rated symptoms as disease- or treatment-related. Patients completed quality-of-life and performance status measures. RESULTS: A 19-item index was produced from symptoms that were rated as most important by patients or clinicians. It includes three subscales: disease-related symptoms (DRS), treatment side effects (TSE), and general function and well-being (FWB). Internal consistency was good for the full instrument (α = 0.83), the DRS subscale (α = 0.76), and the FWB subscale (α = 0.78) but lower for the TSE subscale (α = 0.59). Convergent validity was demonstrated through correlations with the FACT-General. Patients with differing performance status were distinguished by the total score (F2,47 = 17.37; P < .0001), the DRS subscale (F2,47 = 14.22; P < .0001), and the FWB subscale (F2,47 = 13.40; P < .0001) but not the TSE subscale (F2,47 =1.48; P = 0.2380). CONCLUSIONS: The National Comprehensive Cancer Network/FACT-Kidney Symptom Index 19 combines symptoms deemed most important by patients and clinicians. Preliminary evidence suggests that the total score and DRS and FWB subscales are reliable and valid as summary indexes. The TSE subscale may be least relevant given the advent of newer therapies.
Authors: David Cella; Susan Yount; Hongyan Du; Rahul Dhanda; Kathleen Gondek; Katie Langefeld; Jacquelyn George; William P Bro; Celeste Kelly; Ronald Bukowski Journal: J Support Oncol Date: 2006-04
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: David Cella; Susan Yount; Penny S Brucker; Hongyan Du; Ronald Bukowski; Nicholas Vogelzang; William P Bro Journal: Value Health Date: 2007 Jul-Aug Impact factor: 5.725
Authors: David Cella; Diane Paul; Susan Yount; Rodger Winn; Chih-Hung Chang; Donald Banik; Jane Weeks Journal: Cancer Invest Date: 2003 Impact factor: 2.176
Authors: Thomas M Atkinson; Charissa F Andreotti; Kailey E Roberts; Rebecca M Saracino; Marisol Hernandez; Ethan Basch Journal: Support Care Cancer Date: 2015-08-28 Impact factor: 3.603
Authors: David Cella; Viktor Grünwald; Bernard Escudier; Hans J Hammers; Saby George; Paul Nathan; Marc-Oliver Grimm; Brian I Rini; Justin Doan; Cristina Ivanescu; Jean Paty; Sabeen Mekan; Robert J Motzer Journal: Lancet Oncol Date: 2019-01-15 Impact factor: 41.316
Authors: Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier Journal: N Engl J Med Date: 2018-03-21 Impact factor: 91.245
Authors: David Cella; Robert J Motzer; Cristina Suarez; Steven I Blum; Flavia Ejzykowicz; Melissa Hamilton; Joel F Wallace; Burcin Simsek; Joshua Zhang; Cristina Ivanescu; Andrea B Apolo; Toni K Choueiri Journal: Lancet Oncol Date: 2022-01-12 Impact factor: 54.433
Authors: David Cella; Bernard Escudier; Nizar M Tannir; Thomas Powles; Frede Donskov; Katriina Peltola; Manuela Schmidinger; Daniel Y C Heng; Paul N Mainwaring; Hans J Hammers; Jae Lyun Lee; Bruce J Roth; Florence Marteau; Paul Williams; John Baer; Milan Mangeshkar; Christian Scheffold; Thomas E Hutson; Sumanta Pal; Robert J Motzer; Toni K Choueiri Journal: J Clin Oncol Date: 2018-01-29 Impact factor: 44.544
Authors: Robert J Motzer; Konstantin Penkov; John Haanen; Brian Rini; Laurence Albiges; Matthew T Campbell; Balaji Venugopal; Christian Kollmannsberger; Sylvie Negrier; Motohide Uemura; Jae L Lee; Aleksandr Vasiliev; Wilson H Miller; Howard Gurney; Manuela Schmidinger; James Larkin; Michael B Atkins; Jens Bedke; Boris Alekseev; Jing Wang; Mariangela Mariani; Paul B Robbins; Aleksander Chudnovsky; Camilla Fowst; Subramanian Hariharan; Bo Huang; Alessandra di Pietro; Toni K Choueiri Journal: N Engl J Med Date: 2019-02-16 Impact factor: 91.245
Authors: Robert J Motzer; Bernard Escudier; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Thomas Powles; Frede Donskov; Elizabeth R Plimack; Philippe Barthélémy; Hans J Hammers; Saby George; Viktor Grünwald; Camillo Porta; Victoria Neiman; Alain Ravaud; Toni K Choueiri; Brian I Rini; Pamela Salman; Christian K Kollmannsberger; Scott S Tykodi; Marc-Oliver Grimm; Howard Gurney; Raya Leibowitz-Amit; Poul F Geertsen; Asim Amin; Yoshihiko Tomita; M Brent McHenry; Shruti Shally Saggi; Nizar M Tannir Journal: J Immunother Cancer Date: 2020-07 Impact factor: 13.751
Authors: Guillaume Mouillet; Joëlle Fritzsch; Sophie Paget-Bailly; Astrid Pozet; Ikram Es-Saad; Aurelia Meurisse; Dewi Vernerey; Kristina Mouyabi; Diane Berthod; Franck Bonnetain; Amélie Anota; Antoine Thiery-Vuillemin Journal: Health Qual Life Outcomes Date: 2019-02-04 Impact factor: 3.186